NEW YORK (GenomeWeb News) – Invitrogen said Monday that it will collaborate with researchers at Genome Quebec and the Montreal Heart Institute Pharmacogenomics Centre on a pharmacogenomics research project.
Specifically, Invitrogen said that the partners aim to develop novel methodologies and reagents for targeted medical resequencing.
Researchers at the Pharmacogenomics Centre are trying to identify new SNPs within around 200 specific ADME/Tox-related genes that affect drug metabolism. The collaboration with Invitrogen is meant to accelerate this effort, the partners said in a statement.
“This collaboration offers Invitrogen the opportunity to work closely with thought leaders in the field of pharmacogenomics and to better understand this emerging area of research,” said Rob Bennett, Invitrogen’s vice president of advanced sequencing applications, in a statement.